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Abstract
Background: The use of cardiac resynchronization therapy (CRT) and implantable cardi-
overter-defibrillator (ICD) for advanced heart failure (HF) is increasing. Renal dysfunction 
is a common condition in HF which is associated with a worse survival. The study aims at 
identifying in patients with advanced HF treated with CRT the effect of baseline glomerular 
filtration rate (GFR), GFR improvement and left ventricular ejection fraction (LVEF) change, 
after 6-months of CRT implant, on survival.
Methods: The study population consisted of 375 advanced HF patients who received a CRT 
between 1999 and 2009, of these 277 received also an ICD implant. Clinical characteristics 
(New York Heart Association [NYHA] functional class, ischemic vs. non-ischemic etiology, 
atrial fibrillation, diabetes, hypertension, LVEF, QRS duration and GFR were recorded. The 
use of common used drugs was evaluated. Cox proportional hazards analysis was calculated 
in order to evaluate variables associated to mortality.
Results: During a median follow-up of 43.0 months, 93 (24.8%) patients died. Patients 
deceased during the study had at baseline higher NYHA class and lower LVEF and GFR.  
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In Cox regression analysis, GFR predicts long-term mortality (hazard ratio [HR] 0.983; 95% 
confidence interval [CI] 0.969–0.998; p = 0.023) independently from the effect of others covari-
ates. In addition, a positive GFR improvement 6 months after CRT implant is significantly 
associated with a lower hazard of mortality (for each 10 mL/min of GFR improvement HR 
0.86; 95% CI 0.75–0.99; p = 0.038).
Conclusions: GFR is a significant predictor of mortality in advanced HF patients who re-
ceived CRT. A GFR improvement 6 months after CRT implant is significantly associated with 
a lower hazard of mortality. (Cardiol J 2015; 22, 4: 459–466)
Key words: cardiac resynchronization therapy, heart failure, outcome,  
renal function
Introduction
Controlled trials have demonstrated that car-
diac resynchronization therapy (CRT), achieved 
by biventricular (left ventricular [LV] and right 
ventricular [RV]) pacing improves survival, mor-
bidity, symptoms, quality of life, exercise capacity, 
cardiac structure and function in heart failure (HF) 
patients with wide QRS complex [1–8]. However, 
some patients do not benefit from CRT, particularly 
those with HF of ischemic etiology [9, 10]. Con-
sequently, extensive research has been conducted 
to identify predictors of midterm outcomes, such 
as improvement in New York Heart Association 
(NYHA) functional class or improvement in LV 
ejection fraction (LVEF) [6].
Impairment of kidney function is highly preva-
lent in patients with advanced HF at the moment 
of CRT implant and it ranges from 40% [11] to 71% 
[12]. Impaired kidney function has been associ-
ated with poor prognosis in patients with HF [13]. 
Recently, it has been demonstrated that patients 
who had significant LVEF reverse remodeling after 
CRT experienced improvements in renal function 
and survival [11]. However, the independent effect 
of glomerular filtration rate (GFR) on positive re-
sponse to CRT treatment and-long term mortality 
is poorly investigated in HF patients.
In the present study, we evaluated the effect 
of kidney function (baseline GFR and GFR im-
provement after CRT implantation) on mortality 
in advanced HF patients who underwent CRT 
implantation.
Methods
Patient populations
Between November 1999 and March 2009, 
375 patients with HF who received CRT at the Divi-
sion of Cardiology, University of Florence, Italy and 
at the Istituto Clinico Humanitas IRCCS — Rozza-
no, Milan, Italy were consecutively included in the 
study. Implantable cardioverter-defibrillator (ICD) 
were implanted in 277 patients. All the patients had 
systolic HF and were in NYHA functional class ≥ II. 
Patients in NYHA functional class II received CRT 
if they were clinically unstable or had recurrent 
episodes of HF. All patients had a LVEF ≤ 35% 
and QRS complex ≥ 120 ms. Patients with primar-
ily significant valve heart disease were excluded. 
Before CRT, patients were on optimized medi-
cal therapy for HF with the maximum tolerated 
doses of angiotensin-converting enzyme inhibitor 
(ACEI); angiotensin receptor blockers II (ARB-II), 
and beta-blockers, and received diuretics as needed 
to avoid signs and symptoms of fluid retention. 
The great majority (99.5%) of the implants was 
endocardial and the target pacing site for the LV, 
the lateral/posterior lateral region, was reached in 
the majority of the patients. Because indication for 
ICD therapy changed over time, patients received 
appropriate device based on currently available 
evidence and guidelines [6]. The atrio-ventricular 
pacing interval was adjusted before discharge to 
optimize hemodynamic parameters during Doppler 
echocardiography. A complete patients evaluation 
was done before CRT implantation (baseline) 
and at the follow-up (6 months) and included the 
assessment of LVEF and QRS duration, NYHA 
functional class, etiology (coronary heart disease 
vs. cardiomyopathy), presence of atrial fibrillation, 
diabetes, hypertension, and GFR computed using 
the Modification of Diet in Renal Disease Study 
equation (MDRD) [14]. GFR improvement was 
assessed considering the change between basal 
determination and follow-up.
All 375 patients were followed up and mor-
tality was assessed retrospectively, after CRT 
implant, until July 2011. A patient with a LVEF 
increment ≥ 10% 6 months after CRT implantation 
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was considered as “Responder”. All-cause mortal-
ity and hospital admission for decompensate HF 
were recorded as events. The primary end point 
was the all cause mortality recorded from family 
members or from the referring physician.
This study was approved by local Institutional 
Review Board.
Statistical analysis
Continuous variables are reported as mean 
± standard deviation. Categorical data are expressed 
as frequencies and percentages. Two-tailed tests 
of significance are reported, and p values lower 
than 0.05 are considered statistically significant. 
Univariate comparison of baseline clinical and 
echo-cardiographic characteristics stratified by all-
cause mortality was performed by Student’s t test 
or c2 as appropriate. The Cox proportional hazards 
(PH) regression model was used to get hazard 
ratios (HR) and to analyze survival time free from 
all cause death. Cox PH assumption was evaluated 
by testing time-varying effect of each covariate. 
Non linearity in the relation between explanatory 
and outcome variables has been investigated by 
the multivariable fractional polynomials (MFP) 
algorithm [15, 16].
An extension of this algorithm MFP time has 
been employed to model the time-varying effect 
when testing the PH assumption [17]. Model 
building and variables selection was achieved by 
subject-matter knowledge and data driven model 
selection. Age and sex are regarded as “confound-
ers” (as such are forced in the model irrespective of 
the statistical significance) while all the remaining 
variables, considered “effect modifiers”, are tested 
before inclusion in the final model. First level 
interaction effect was planned and tested for the 
variables (marked with an asterisk in Table 2) by 
means of the MFP interaction, a further extension 
of the MFP procedure [18].
The MFP algorithms, employed for variables 
selection, for non linear continuous variable mod-
eling and for interaction testing, is a systematic 
approach for multivariate model building based on 
a closed test procedure which maintains approxi-
mately the correct type I error rate [16].
In order to assess the discrimination ability of 
the final Cox model the R2 measure of the explained 
variation has been computed [19].
Three 1st level interaction terms, constructed 
using the variables (marked with an asterisk in 
Table 2), have been tested in the Cox model. The 
first and the second, the Responder*GFR and the 
Responder*LVEF, to assess if being classified as 
responder exerts a modulation effect on the im-
pact over survival of the GFR, the first, and of the 
LVEF, the second, (or vice versa). The third, the 
GFR*LVEF, to asses if varying the levels of one of 
these variables modify the effect over the survival 
of the other. None of these interactions reached 
a statistically significant degree of association.
In the final Cox model that includes the 
2 covariates gathered at 6-month follow-up (namely 
the GFR improvement and the responder status), 
8 patients with missed values of these factors (be-
cause of censoring [5 patients] or death [3 patients] 
before 6-month follow-up) were excluded from the 
analysis (listwise missing values exclusion).
All continuous variables, namely the baseline 
GFR, the GFR improvement and the LVEF, were 
tested for linearity of the effect by means of the 
fractional polynomial algorithm [15, 16] none 
showed a significant non linear association.
The final Cox model, built in order to evaluate 
the effect on mortality, includes, in addition to the 
a priori incorporated age and sex as confounder 
variables, all the variables tested as effect modifier 
showing a statistically significant level.
All the variables included in the final model 
were tested for the PH assumption, none violated 
it. In order to have a comprehensive view of the 
relative weight of each factor on the survival curve, 
the HR of the significant continuous variables 
included in the final Cox models were related to 
clinically meaningful variations, 10 mL/min for 
basal GFR and GFR improvement, 5% for LVEF.
Statistical analysis was performed with the 
STATA 11.2 software (Stata Corp LP).
Results
Mean age of the 375 patients with advanced HF 
was 66.6 ± 10.1 years (range 21–86). All patients 
were observed for a median of 43.0 months (min: 2, 
max: 135), 93 (24.8%) patients died. Mortality rate 
at 1 and 5 years was 3.1% and 29.4%, respectively. 
All patients had depressed LVEF (28.0 ± 5.4), 
symptomatic advanced HF (NYHA I: 0%, NYHA II: 
18.9%, NYHA III: 65.3%, NYHA IV: 15.7%), and 
a wide QRS complex (154.7 ± 30.5 ms). Atrial 
fibrillation was present in 15.7%, while ischemic 
HF was present in 183 (48.8%) patients. ICD was 
implanted in 277 patients. Mean GFR was 59.9 ± 
± 23.5 and 197 (52.7%) had chronic kidney disease 
(CKD) (defined as a GFR of ≤ 60 mL/min/1.73 m2) 
at the time of device implantation. Prevalence of 
patient with a LVEF increment ≥ 10% 6 months 
after CRT implantation (“Responder”) was 36.3% 
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(Table 1). Diuretics were used in 344 (91.7%) pa-
tients, beta-blockers in 284 (75.7%), ACEI in 260 
(69.3%) and ARB-II in 86 patients (22.9%).
The final Cox PH regression model (Table 2) 
shows that having a baseline GFR 10 mL/min 
greater is significantly associated with a 12% 
smaller hazard of all cause cumulative mortality 
(for each 10 mL/min increase HR 0.88; 95% CI 
0.78–0.98; p = 0.003). In addition, a positive GFR 
improvement 6 months after CRT implant is sig-
nificantly associated with a lower mortality risk 
(for each 10 mL/min of GFR improvement HR 0.86; 
95% CI 0.75–0.99; p = 0.038). Moreover, patients 
experiencing a 6 months improvement of GFR 
show a positive effect on survival independently 
from the baseline values. Higher LVEF (for each 
5% LVEF increase HR 0.65; 95% CI 0.53–0.79; 
p < 0.001) and use of beta-blockers (HR 0.57; 95% 
CI 0.37–0.88; p = 0.013) are associated with lower 
hazard. Interestingly, patients presenting with the 
diagnosis of hypertension showed a lower hazard 
(HR 0.55; 95% CI 0.35–0.85; p = 0.015). Being 
classified as responder to CRT implant resulted 
in a significant 57% lower hazard (HR 0.57, 95% 
CI 0.35–0.93).
The R2 computed for the final model (a meas-
ure — on the log relative hazard scale — of the 
variation explained by the covariates included 
in the model) is 0.28, i.e. almost one third of the 
variance is explained by the variables included in 
the model. Figures 1 and 2 show survival curves 
relative to, respectively, three baseline GFR levels 
and three different GFR improvements 6 months 
after CRT implant, namely one with no changes 
and, of the remaining two, one improving and one 
declining both by an amount equal to one standard 
deviation (18 mL/min).
Discussion
The study supports the evidence that renal 
dysfunction at the time of CRT implant is associ-
ated with a poorer overall survival. The magnitude 
of the HR involved 12% smaller hazard every 
Table 1. Baseline characteristics of 375 patients enrolled in the study.
Clinical variables All (n = 375) Survived (n = 295) Died (n = 80) P
Age [years] 66.6 ± 10.1 66.3 ± 10.3 67.8 ± 9.3 0.249
Men 303 (80.8%) 239 (81.0%) 64 (80.0%) 0.838
QRS duration [ms] 154.7 ± 30.5 154.4 ± 27.5 156.1 ± 40.7 0.687
Atrial fibrillation 59 (15.7%) 40 (13.6%) 19 (23.8%) 0.026
NYHA functional class 3.0 ± 0.6 2.9 ± 0.6 3.2 ± 0.6 0.000
Etiology (CHD vs. cardiomyopathy)
CHD 183 (48.8%) 150 (50.8%) 42 (52.8%) 0.793
Medical therapy:
ICD 277 (73.9%) 228 (77.3%) 49 (61.3%) 0.004
Beta-blockers 284 (75.7%) 237 (80.3%) 47 (58.8%) 0.000
ACEI 260 (69.3%) 209 (70.8%) 51 (63.8%) 0.222
ARB-II 86 (22.9%) 68 (23.1%) 18 (22.5%) 0.917
Diuretics 344 (91.7%) 269 (91.2%) 75 (93.8%) 0.460
Digoxin 138 (36.8%) 90 (32.5%) 42 (53.2%) 0.001
Amiodarone 87 (23.2%) 64 (21.7%) 23 (29.1%) 0.166
LVEF [%] 28.0 ± 5.40 28.5 ± 5.1 26.1 ± 6.2 0.000
Basal GFR MDRD 59.9 ± 23.5 61.6 ± 24.2 53.4 ± 19.4 0.005
GFR improvement 0.92 ± 17.8 1.68 ± 17.4 –1.37 ± 18.9 0.150
Diabetes 106 (28.3%) 81 (27.5%) 25 (31.3%) 0.504
Hypertension 185 (49.3%) 154 (52.2%) 31 (38.8) 0.033
Responder (≠ LVEF 10%) 136 (36.3%) 103 (37.2%) 31 (33.3) 0.497
Mean ± standard deviation if continuous variable, number of elements and percent of the overall if counting variable; NYHA — New York 
Heart Association;  CHD — coronary heart disease; ICD — implantable cardioverter-defibrillator; ACEI — angiotensin-converting enzyme  
inhibitor; ARB-II — angiotensin receptor blockers II; LVEF — left ventricular ejection fraction; GFR — glomerular filtration rate; Basal GFR 
MDRD — GFR from Modification of Diet in Renal Disease (MDRD) Study equation; GFR improvement — change between basal determination 
and follow-up; Responder  — a patient with a LVEF increment ≥ 10% 6 months after CRT implantation
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10 mL/min of GFR increase, denotes a clinically 
moderate effect exerted by impaired renal function 
on mortality in patients with advanced HF after 
CRT implant. This consideration becomes relevant 
in view of the high prevalence of kidney dysfunction 
in HF patients, 52.7% in our study. Moreover, 
patients experiencing a 6 months improvement of 
GFR show a positive effect on survival that, indeed, 
is independent from the baseline values, supporting 
the proposition that therapies oriented to amelio-
rate kidney function are potentially beneficial to 
the overall survival. Moreover, baseline GFR is 
Table 2. Cox multivariate regression on mortality.
Variables HR (95% CI) P
Age 1.01 (0.99–1.04) –
Male sex 0.96 (0.56–1.66) –
Etiology (CAD vs. cardiomyopathy) 1.04 (0.65–1.64) 0.884
NYHA functional class 1.29 (0.88–1.89) 0.195
Atrial fibrillation 1.25 (0.76–2.09) 0.380
ICD 0.81 (0.49–1.32) 0.397
Beta-blockers 0.57 (0.37–0.88) 0.013
ACEI 0.76 (0.49–1.18) 0.237
ARB-II 0.64 (0.34–1.22) 0.174
Diuretics 1.27 (0.54–2.98) 0.590
Digoxin 1.01 (0.64–1.58) 0.966
Amiodarone 1.24 (0.76–2.02) 0.386
LVEF (HR relative to 5% change)* 0.65 (0.54–0.79) < 0.001
Basal GFR (HR relative to 10 mL/min)* 0.88 (0.78–0.98) 0.003
GFR improvement (HR relative to 10 mL/min) 0.86 (0.75–0.99) 0.038
Diabetes mellitus 1.22 (0.75–1.96) 0.415
Hypertension 0.54 (0.35–0.85) 0.008
Responder (≠ LVEF ≥ 10%)* 0.57 (0.35–0.93) 0.011
*The asterisk mark variables involved in 1st level interaction assessment; HR — hazard ratio; CI — confidence interval; CHD — coronary heart 
disease; ICD — implantable cardioverter-defibrillator; ACEI — angiotensin-converting enzyme inhibitor; ARB-II — angiotensin receptor block-
ers II; LVEF — left ventricular ejection fraction; GFR — glomerular filtration rate; Basal GFR — GFR from Modification of Diet in Renal Disease 
(MDRD) Study equation; GFR improvement (HR relative to 10 mL/min change) — change between basal determination and follow-up;  
Responder — a patient with a LVEF increment ≥ 10% 6 month after CRT implantation
Figure 2. Cumulative survival to all-cause death for 
three different levels (0 ± 1 standard deviation [SD]) of 
glomerular filtration rate (GFR) improvement adjusted 
for all the remaining variables of the final Cox model.
Figure 1. Cumulative survival to all-cause death for 
three different levels of glomerular filtration rate (GFR) 
adjusted for all the remaining variables of the final Cox 
model.
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a predictor of positive response to the CRT therapy 
(i.e. heart pump function improvement), resulting 
in a patient with a relevant (10%) increase of the 
LVEF 6 months after CRT implant. All these evi-
dences make GFR an important parameter in the 
evaluation of CRT implant, suggesting that CRT 
implant should be performed before evident kidney 
dysfunction if we positively modify prognosis.
Heart failure, renal function and CRT
Our study shows that a large part of patients 
with advanced HF (52.7%) had CKD at the time of 
device implantation, confirming data from previous 
studies, where CKD was highly prevalent among 
HF patients. It has been estimated that as many 
as 25% to 50% of patients with HF have impaired 
renal function (creatinine clearance < 60–75 mL/ 
/min/1.73 m2) [20–22]. Recently, a systematic 
review has examined the effects of CRT in CKD 
patients (eGFR < 60 mL/min/1.73 m2) with HF. 
Eighteen studies (14 observational studies and 
4 randomized clinical trials) were considered. The 
analysis demonstrated a modest improvement in 
estimated GFR with CRT among CKD patients 
(mean difference 2.30 mL/min/1.73m2). Similarly, 
there was a significant improvement in LVEF with 
CRT in CKD patients (mean difference 6.24%). 
Subgroup analysis of 3 randomized clinical trials 
reported lower rates of death or hospitalization for 
HF with CRT in the CKD population [23].
Heart failure, renal function,  
CRT and mortality
GFR improvement was associated with im-
proved survival.
Moreover, our findings are consistent with pre-
vious observations that worsening renal function 
confers worse outcomes in HF. Data derived from the 
SOLVD (Studies of LV Dysfunction) trial revealed 
that in HF patients with a LVEF < 35%, a total of 
32% of patients had a GFR < 60 mL/min/1.73 m2, 
moreover, a 10 mL/min/1.73 m2 lower GFR was as-
sociated with a 1.064 (95% CI 1.033–1.096) higher 
risk of mortality in these patients [24]. The cur-
rently observed HR for GFR (for each 10 mL/min 
increase HR 0.88; 95% CI 0.78–0.98; p = 0.003) 
is fairly higher than that reported by SOLVD, but 
may be attributed to the fact that in the SOLVD 
trial, only 12% of patients were in NYHA functional 
class III or IV, vs. 81% in our study. Similar observa-
tions as in SOLVD were noted in another large trial, 
CHARM (Candesartan in Heart Failure: Assess-
ment of Reduction in Mortality and Morbidity) [25], 
where around 35% of 2,680 patients had a GFR 
< 60 mL/min/1.73 m2, and this was associated with 
increased mortality during long-term follow-up 
(HR 1.50; 95% CI 1.15–2.00) [25].
Lin et al. [12] demonstrate in 482 CRT device 
implantations, 71% with CKD (defined as a GFR of 
≤ 60 mL/min/1.73 m2), that CKD at the time of CRT 
implantation was associated with worse survival 
after 3 years of follow-up (57 vs. 72%; p < 0.01). 
In our study, we observed a lower mortality (29.4% 
after 5 years of follow-up) and this could be in part 
due to the lower rate of CKD prevalence in our 
sample (52.7 vs. 71%) and the younger age (66 
vs. 71).
Renal function improvement  
after CRT and mortality
Estimated GFR improved modestly in patients 
with baseline CKD (mean change 0.95 ± 8.71 mL/ 
/min/1.73 m2) and decreased modestly in patients 
without baseline CKD (mean change GFR −1.99 
± 11.23 mL/min/1.73 m2, p = 0.03). A similar trend 
is observed in our study where estimated GFR im-
proved 0.92 ± 17.8 mL/min/1.73 m2, after 6 months 
of CRT implant. In patients with baseline CKD, 
there was an improvement (mean change 4.24 ± 
± 14.2 mL/min/1.73 m2), while  in patients without 
baseline CKD there was a decrease (mean change 
GFR −3.01 ± 20.9 mL/min/1.73 m2, p = 0.00) 
(data not shown).
Adelstein et al. [26] found a similar result to 
our study among CRT-D recipients, overall sur-
vival improved incrementally with higher baseline 
GFR (for each 10 mL/min/1.73 m2 increase, cor-
rected HR 1.21; 95% CI 1.13–1.30; p < 0.0001). 
Moreover, the survival benefit was associated 
with improved renal and cardiac function. CRT 
recipients with GFR ≥ 60 mL/min/1.73 m2 derived 
significant echocardiographic benefit but experi-
enced a GFR decline, whereas those with GFR 
< 30 mL/min/1.73 m2 had no echocardiographic 
benefit but an improvement in GFR. Similarly, we 
found that a positive GFR improvement, 6 months 
after CRT implant, is significantly associated with 
a lower hazard (for each 10 mL/min/1.73 m2 of 
GFR improvement HR 0.86; 95% CI 0.75–0.99; 
p = 0.038). A similar result is also found by Hosoda 
et al. [20] who demonstrated in 67 consecutive 
patients who underwent CRT that advanced renal 
insufficiency was an independent predictor of car-
diac mortality combined with HF hospitalization 
(odds ratio 3.01, p = 0.008). Subgroup analysis in 
the baseline advanced renal insufficiency group 
revealed that patients with preserved renal func-
tion by CRT (< 10% reduction in estimated GFR) 
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had a higher rate of decrease of LV end-systolic 
diameter (–14.0% vs. –0.8%, p = 0.023) and lower 
cardiac mortality combined with HF hospitalization 
(log-rank: p = 0.029) compared with patients with 
deterioration of renal function (≥ 10% reduction 
in estimated GFR). These results are in line with 
our observation, we demonstrated that different 
GFR changes 6 months after CRT implant are an 
independent predictor of mortality (HR 0.86; 95% 
CI 0.75–0.99; p = 0.038).
An unresolved question is if renal impairment 
associated with HF could be improved by CRT 
and this effect could improve survival. Our study 
demonstrated that the proportion of patients in 
whom estimated GFR improved after CRT implant 
experienced lower mortality, supporting the propo-
sition that therapies oriented to ameliorate kidney 
function are potentially beneficial to the overall sur-
vival, independently from cardiac function. Kidney 
function is strongly influenced by renal perfusion 
improved by CRT which could induce systemic 
hemodynamic benefits. This hemodynamic benefit 
is most likely exerted by improvement in LV sys-
tolic function and/or reduction in mitral regurgita-
tion. Fung et al. [21] reported that, after 3 months 
of CRT, patients with reverse remodeling (defined 
as at least 10% reduction in LV end-systolic vol-
ume), had a mean increase of GFR from an average 
of 51.7 to 54.2 mL/min/1.73 m2, whereas patients 
without reverse remodeling had a decrease from 
a mean 61.9–48.8 mL/min/1.73 m2. The major limi-
tation of this study was the lack of a control group. 
Van Bommel et al. [11] in a subset of 133 patients, 
with 6-month blood sample data, observed a signifi-
cant deterioration in renal function (GFR change, 
–4.7 mL/min/1.73 m2) among patients who did 
not respond to CRT with LV reverse remodeling, 
whereas GFR did not change significantly during 
the 6 months of follow-up among CRT responders. 
Recently, Eisen et al. [22] demonstrated on 730 ICD 
and 453 CRT-D patients that mean estimated GFR 
after 1-year follow-up decreased by 8.0 ± 4.3 mL/ 
/min/1.73 m2 in ICD patients (p = 0.06) and by 
1.8 ± 1.3 mL/min/1.73 m2 in patients with CRT-D 
(p = 0.2). The GFR changes differed significantly 
between CRT responders and non-responders 
suggesting that this clinical parameter could help 
to determine which patient will respond to CRT, 
and which patient might not respond indicating 
a pathogenic interconnection between heart and 
kidney [11, 27–29].
In our study, we demonstrate that a positive 
GFR improvement 6 months after CRT implant 
is significantly associated with a lower hazard of 
mortality (for each 10 mL/min of GFR improvement 
HR 0.86; 95% CI 0.75–0.99; p = 0.038).
Limitations of the study
Some limitations of the present study have to 
be addressed. First, the present report is based on 
a retrospective approach. Therefore, the observation 
we made cannot prove causality per se. Second, the 
choice to implant CRT-D vs. CRT-P may affect the 
survival and may constitute a bias difficult to sort 
out even with control in the multivariate model. 
Third, the exclusion of 8 patients censored before 
or not surviving 6 months of follow-up may repre-
sent a “survival bias”, however, the small amount 
of patients involved, and the lack of a specific 
distinctive tract in these patients (LVEF and basal 
GFR in the 3 deceased and in the 5 censored are 
LVEF  26.6 ± 6.0, basal GFR 57.7 ± 29.9 and LVEF 
28.4 ± 5.1, basal GFR 60.6 ± 20.9, respectively) 
suggest that a negligible influence on the overall 
results that we observed is expected.
Conclusions
In our study population, we demonstrate that 
GFR predicts long-term mortality in patients with 
advanced HF treated with CRT. The baseline GFR 
differed significantly between CRT responders and 
non-responders suggesting that this clinical pa-
rameter could help to determine which patient will 
respond to CRT, and in turn could affect mortality. 
A GFR improvement 6 months after CRT implant 
is significantly associated with a lower hazard of 
mortality. Whether early placement of CRT will 
also determine delayed onset of CKD, and a pos-
sible mortality benefit, deserves further study.
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